Peptides for meniscus injury: Frequently asked questions

White-zone tears are the strongest indication for BPC-157 because angiogenesis is the biological bottleneck. Research doses of 400–500 mcg daily via subcutaneous injection near the injury site (or systemically if local administration isn't feasible) for 8–12 weeks aim to extend capillary networks into the avascular tissue. Combine with TB-500 in the first 4–6 weeks to accelerate the migration of endothelial cells and fibroblasts once new vessels begin forming.

Start with GHK-Cu at 1.5–3 mg three times weekly for the first 8 weeks post-op to address surgical inflammation and support scar tissue remodeling. Add BPC-157 at 300–500 mcg daily if imaging shows poor vascular infiltration at the surgical site. The goal is capillary formation in the debrided area. TB-500 is less relevant post-meniscectomy unless there's concurrent ligament or cartilage damage requiring acute repair signaling.

Chronic degeneration involves sustained low-grade inflammation and collagen breakdown. GHK-Cu at 1–2 mg twice weekly addresses both by downregulating matrix metalloproteinases (MMPs) and upregulating tissue inhibitors of metalloproteinases (TIMPs). BPC-157 and TB-500 are secondary priorities unless acute flare-ups or partial tears develop. The remodeling phase in chronic conditions can extend 12–24 months, making GHK-Cu the most cost-effective long-term option.

Use BPC-157 as the lead peptide because the injury site cannot access systemically circulating growth factors without local angiogenesis. BPC-157's VEGF upregulation mechanism creates new capillary beds from the meniscal periphery toward the defect zone, effectively converting a white-white injury into a red-white injury over 3–4 weeks. Rodent studies show capillary density increases by 3.2× at day 14 with BPC-157 administration. This is the only mechanism that addresses the fundamental vascular limitation of inner meniscal tears.

Do not introduce TB-500 or GHK-Cu until inflammatory markers (elevated IL-1β, TNF-α, persistent effusion) resolve. Peptides that promote cellular migration and collagen synthesis are ineffective in a catabolic environment where MMPs degrade tissue faster than it forms. Use non-steroidal anti-inflammatory protocols or consider low-dose BPC-157 for its nitric oxide modulation, which shifts macrophage phenotype from M1 (inflammatory) to M2 (repair-promoting) without suppressing the immune response entirely.

Discard the vial. Peptide stability degrades irreversibly above 8°C once reconstituted with bacteriostatic water. BPC-157 and TB-500 are linear polypeptide chains susceptible to proteolytic cleavage at ambient temperatures, which breaks the amino acid sequence and eliminates biological activity. Lyophilized (freeze-dried) peptides tolerate room temperature for short periods, but reconstituted solutions must be refrigerated at 2–8°C and used within 28 days. Temperature excursions cannot be reversed. The peptide is no longer structurally intact.